HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Euro Q2 Earnings Preview: GSK, Sanofi, Bayer And Reckitt

Executive Summary

Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt are all hoping for a sales boost in Q2 following a difficult Q1 due to the almost non-existent cough and cold season. This earnings preview highlights what to look out for as these four firms report their second-quarter results over the coming weeks.

You may also be interested in...



GSK Remains Open To Consumer Healthcare Sale As It Prepares To Name CEO

Responding directly to a call from an activist investor to consider selling Consumer Healthcare, GSK says it will evaluate any acquisition proposals it receives. A six-month long process to appoint a CEO to lead the new standalone OTC business is also nearing its conclusion.

Activist Investor Urges GSK To Consider Consumer Healthcare Sale

Activist investor Elliot Management – which has built up a sizeable stake in GSK – is urging the UK-based pharma giant to remain open to offers for its Consumer Healthcare business and to consider both internal and external candidates for the leadership of the standalone unit. 

OTC Allergy Switch Approved For Bayer In US

CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.

Related Content

Topics

UsernamePublicRestriction

Register

RS151568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel